Kymera Therapeutics (KYMR) Income Statement: Revenue & Earnings

Kymera Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Kymera Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	47.07	78.59	46.83	72.83	34.03
Cost of Revenue	240.25	189.08	164.25	137.02	62.11
Gross Profit	-193.18	-110.49	46.83	72.83	34.03
Operating Expenses
Research & Development	240.25	189.08	164.25	137.02	62.11
Selling, General & Administrative	63.53	55.04	43.83	36.35	27.28
Operating Expenses	63.53	55.04	208.08	173.36	80.34
Operating Income	-256.71	-165.53	-161.26	-100.53	-46.30
Other Income/Expense
Interest Income	38.03	18.76	6.62	0.49	0.83
Interest Expense	-0.25	-0.20	0.18	-0.18	-0.12
Other Income/Expense	-4.93	-18.57	-6.45	-0.31	-0.71
Income
Income Before Tax	-223.86	-146.96	-154.81	-100.22	-54.64
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-223.86	-146.96	-154.81	-100.22	-45.59
Net Income - Continuous Operations	-223.86	-146.96	-154.81	-100.22	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-250.74	-163.47	-151.66	-97.65	-43.72
EBIT	-256.71	-165.53	-154.63	-100.04	-45.48
Depreciation & Amortization	5.97	2.07	3.00	2.40	1.80
Earnings Per Share
Basic EPS	-3.00	-3.00	-3.00	-2.00	-3.00
Diluted EPS	-3.00	-3.00	-3.00	-2.00	-3.00
Basic Shares Outstanding	75.04	58.37	53.93	47.99	17.35
Diluted Shares Outstanding	75.04	58.37	53.93	47.99	17.35